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ABSTRACT
Introduction Recently, the rate of caesarean sections 
(CS) worldwide has risen and CS- associated complications 
such as niche have increased substantially. Until now, 
evidence- based clinical guidelines for the treatment of 
niche- related symptoms remain absent. In patients with 
postmenstrual spotting, it has not been studied if the 
effect of levonorgestrel 52 mg intrauterine system (LNG- 
IUS 52 mg) is superior to that of hysteroscopy. This study 
will answer the question of whether LNG- IUS 52 mg is 
more effective in improving postmenstrual spotting than 
hysteroscopic niche resection in women with niche- related 
spotting at 6 months after randomisation.
Methods and analysis This is a randomised controlled 
trial. A total of 208 women with postmenstrual spotting 
related to niche in the caesarean uterine scar of at least 
2 mm and residual myometrium of at least 2.2 mm 
evaluated by MRI will be included. Women desiring to 
conceive within 1 year, with contraindications for LNG- IUS 
52 mg or hysteroscopic surgery will be excluded. After 
informed consent is obtained, eligible women will be 
randomly allocated to LNG- IUS 52 mg or hysteroscopic 
niche resection at 1:1. The primary outcome is the 
efficacy in reducing postmenstrual spotting at 6 months 
after randomisation. The secondary outcomes include 
menstrual pattern, total days of blood loss per month, 
rate of amenorrhoea, side effects and complications.We 
will use a Visual Analogue Scale for chronic pelvic pain, 
urological symptoms and women’s satisfaction (five- point 
Likert scale).
Ethics and dissemination The study was approved 
by the local medical ethics committee and by the 
Institutional Review Board of the International Peace 
Maternity and Child Health Hospital, Shanghai, China 
(No. GKLW 2019-08). Participants will sign a written 
informed consent before participation. The results of this 
study will be submitted to a peer- reviewed journal for 
publication.
Trial registration number ChiCTR1900025677.
INTRODUCTION
In the last decades, the rate of caesarean 
sections (CS) worldwide has risen and CS- as-
sociated complications such as niche have 
increased substantially.1 In China, in the 
past 30 years, due to the implementation of 
the family planning policy, the rate of CS 
increased from 2% to 62.5% (1985–2014), 
and in some regions, the rate of CS even 
reached more than 80%, while not all CSs 
are medically indicated.2 3 The rapid rise 
of CS rate has aroused great concern about 
the poor uterine scar healing and potential 
long- term complications of CS. Postmen-
strual spotting related to a niche in the CS 
uterine scar is also called a caesarean scar 
defect (CSD) or isthmocele. The niche was 
first described by Morris in 1995 and was 
defined by the ESGE niche task force group 
Strengths and limitations of this study
 ► This is the first randomised controlled trial that will 
provide evidence for the effectiveness of levonorge-
strel intrauterine system 52 mg versus hysteroscop-
ic niche resection in reducing niche- related spotting 
symptoms.
 ► The trial is adequately based on a representative 
cohort study.
 ► This trial is an open- label trial both for patients and 
for researchers, but uses a blind method to evaluate 
the effect of treatment.
 ► This study will evaluate niches by three- dimensional 
(3D) MRI with the section of only 1 mm and 3D re-
construction to improve the accuracy.
 ► The trial is based in a single centre, which might 
limit the generalisability of the findings.
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as an indentation in the myometrium of at least 2 mm 
at the site of a previous CS scar.4–6 Niches were reported 
in 24%–69% of the women with a previous CS who had 
used transvaginal ultrasonography without intrauterine 
application of saline or gel, while the rate after applica-
tion of intrauterine gel or saline ranged between 56% 
and 78%.7–9 Postmenstrual abnormal uterine bleeding 
(AUB) is the most common symptom, other symptoms 
include menorrhagia, chronic pelvic pain and secondary 
infertility and related adverse effects on women’s phys-
ical and mental health. Niches could be associated with 
pregnancy- related complications such as caesarean scar 
pregnancy, malplacentation, uterine rupture and massive 
haemorrhage that consume a large number of medical 
resources.10
Currently, the treatment of niche- related symptoms 
includes non- reconstruction of lower uterine segment 
(LUS) treatment and reconstruction of LUS treatment. 
Non- reconstructive treatment includes oral contracep-
tive, levonorgestrel intrauterine system (LNG- IUS), 
expectant treatment or hysteroscopic treatment. Recon-
structive treatment includes laparoscopic repair and 
vaginal repair.5 11–13 Evidence- based clinical guidelines for 
the treatment of niche- related symptoms remain absent. 
The specific treatment method should be determined 
according to the patient’s symptoms, fertility desire, 
niche features including size and thickness of the residual 
myometrium. The evaluation of treatment effect still needs 
long- term observation and follow- up.6 In recent years, 
hysteroscopic treatment seems to be a promising option 
in managing of small niches to reduce postmenstrual spot-
ting.11 12 14–17 Resecting the distal rim aims to facilitate the 
outflow of menstrual blood and coagulating the surface of 
vessels in the niche concurrently aims to reduce blood loss 
from these fragile vessels. A randomised controlled trial 
compared hysteroscopic niche resection with expectant 
management in 100 women.The median postmenstrual 
spotting period reduced by 4 days from the baseline and by 
3 days from the control group.12 Both studies reported low 
complication rates that were prospectively evaluated.11 12 
LNG- IUS 52 mg is a long- acting IUS, which has been listed 
in more than 100 countries after its registration in Europe 
in 1990.18 Millions of women received an LNG- IUS 52 mg 
worldwide.19 LNG- IUS 52 mg has been shown to reduce 
menstrual blood loss and dysmenorrhea through the 
suppressive action of levonorgestrel on the endome-
trium proliferation. Even though LNG- IUS 52 mg has 
been proven to be an effective means of reducing AUB, 
and AUB is one mean point in niche- related symptoms, 
evidence that LNG- IUS 52 mg can alleviate the niche- 
related symptoms remains limited.20 21 Concerning LNG- 
IUS 52 mg, a retrospective study of Chen et al including 
six women indicated a positive effect, while Zhang et al 
found that LNG- IUS 52 mg has little improvement on 
shortening postmenstrual spotting based on five patients 
with ING- IUS 52 mg.22 23 Until now, it is unknown which 
therapy is most beneficial for patients with niche- related 
symptoms due to the lack of comparative studies.
OBJECTIVE AND HYPOTHESIS
The objective of the trial is to determine whether LNG- IUS 
52 mg is more effective than a hysteroscopic niche resec-
tion in reducing postmenstrual spotting in women with 
a relatively small niche (residual myometrium ≥2.2 mm) 
and without a desire to conceive within 1 year. Our hypoth-
esis is that in women with a relatively small niche (residual 
myometrium ≥2.2 mm) and without a desire to conceive 
within 1 year, LNG- IUS 52 mg will decrease postmenstrual 
spotting better than hysteroscopic niche resection.
METHODS AND ANALYSIS
Study design and setting
The study is a single- centre randomised controlled supe-
riority trial and will be performed in the International 
Peace Maternity and Child Health Hospital, Shanghai, 
China.
Participants
Inclusion criteria are as follows:
1. Age 18–48 years old.
2. Postmenstrual spotting after CS.
3. MRI has shown: (1) a niche in the anterior wall of LUS 
of at least 2 mm depth and (2) a residual myometrium 
of at least 2.2 mm.
4. Without a desire to conceive within 1 year.
5. Signed informed consent.
Exclusion criteria are as follows:
1. A contraindication for a hysteroscopic niche resection 
or LNG- IUS 52 mg or not willing to receive this type of 
treatment.
2. Women with a positive pregnancy test.
3. Presence of an intrauterine device.
4. A contraindication for general or local anaesthesia.
5. Coagulation disorders that lead to higher risks on 
bleeding or anticoagulant use.
6. A (suspected) malignancy, endometrial polyps, atypi-
cal endometrial cells, cervical dysplasia, hydrosalpinx 
that may communicate with the uterus.
7. Adenomyosis or leiomyoma (the International Federa-
tion of Gynecology and Obstetrics (FIGO) leiomyomia 
subclassification system Type 0, 1, 2, 3) or large leio-
myomas causing the uterine cavity of ≥9 cm that exam-
ined by transvaginal ultrasound or MRI.
8. Endocrine disorders that interfere with the menstrual 
cycle.
9. Irregular menstrual cycle (>35 days or intercycle varia-
tion of 2 weeks or more).
Recruitment and randomisation
Three- dimensional (3D) MRI will be performed as part 
of the routine diagnostic workup for the identification of 
niche (figure 1).
Potential eligible patients visiting the outpatient depart-
ment because of niche- related postmenstrual spotting 
and in whom transvaginal ultrasound has shown a niche 
of at least 2 mm depth will be asked to participate in the 
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trial. After the patients complete the informed consent, 
the examinations and tests will be performed in an outpa-
tient setting by the hospital protocol. The results of these 
tests will be checked by the principal investigators. After 
confirming the presence of the niche and matching the 
inclusion criteria, women will be randomised for LNG- 
IUS 52 mg or hysteroscopic resection. Randomisation 
will be performed by using a web- based Research Elec-
tronic Data Capture (REDCap) system. From an ethical 
perspective, we decided to design the Mirena (LNG- IUS 
52mg)- Hysteroscopic niche resection niche trial (MIHYS 
NICHE trial) as an open- label trial both for patients and 
researchers, but we used a blind method to evaluate the 
effect of treatment.
Niche evaluation
A 1.5 Tesla (Siemens Avanto, Erlangen, Germany) MRI 
system will be used. Both T1- weighted and T2- weighted 
images will be used. Imaging measurement will be 
performed by two experienced observers who are blinded 
to the clinical data. Niche will be measured both in the 
sagittal and in the transversal plane, according to a stan-
dardised protocol as recommended by the international 
niche task force group.24 The length, width and depth of 
niche, the thickness of residual myometrium (TRM), the 
thickness of adjacent myometrium, the presence of any 
branches, the polyp- like structures, the cyst- like forma-
tions in the niche will be registered.
Intervention
Intervention of the LNG-IUS 52 mg group
The LNG- IUS 52 mg will be inserted in an outpa-
tient setting by an experienced gynaecologist. After 
measuring the length of the uterine cavity and the 
dilatation of the cervical canal, an endometrial biopsy 
will be taken for histological examination. According 
to the instructions of LNG- IUS 52 mg and Chinese 
experts’ consensus for clinical application of LNG- 
IUS 52 mg, LNG- IUS 52 mg will be inserted with the 
provided inserter into the uterine cavity within 7 days 
after the onset of the menstruation under ultrasound 
monitoring carefully. If needed, a paracervical block 
will be placed. Ultrasound monitoring will be used to 
ensure the correct localisation of the LNG- IUS 52 mg. 
According to the protocol, patients will not receive any 
additional hysteroscopic resection during a period of at 
least 6 months.
Intervention of the hysteroscopic niche resection group
Patients allocated for hysteroscopic niche resection will 
undergo the procedure under general anaesthesia in 
the day care setting. After dilatation of the endocervix 
Figure 1 Niche measurement in the 3D MRI. (A, B) Sagittal plane; (C, D) transversal plane. Line l: the length of niche, measured 
from the upper rim to the lower rim of niche; line d: the depth of niche, measured from the usual limit of uterine limit to the 
apex of niche; line w: the width of niche, measured the largest width of niche in the transverse plane; line TRM: the thickness 
of residual myometrium, measured from the apex of niche until the serosa; line TAM: the thickness of adjacent myometrium, 
measured from the upper endpoint of niche to the serosa; branch: the lateral branch was defined as the branch of niche, of 
which the widest part <2 mm. TAM, thickness of adjacent myometrium; TRM, thickness of residual myometrium.
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up to Hegar 9 mm, the hysteroscopic resection will be 
performed using a 9 mm resectoscope in a standardised 
way, as described previously.6 For uterine distention, 
0.9% NaCl at a pressure of 100–120 mm Hg will be used. 
The niche will be evaluated by hysteroscopy according 
to a standardised way (presence of dome- shaped scar 
defect, of nodule- like endometrial hyperplasia, and of 
vascularity, valve- like motion or a very high edge). After 
hysteroscopic evaluation, the endometrium specimens 
will be collected for histological examination. A cutting 
loop will be used to resect the distal rim of niche6 and 
the niche surface including all small vessels will be 
coagulated.
Hysteroscopic resection will be performed by two 
gynaecologists with extensive experience in hysteroscopic 
niche resections. The two gynaecologists have completed 
the learning curve (JZ and YL).
Patient and public involvement
Neither the patients nor the public will be involved in 
the study design. They will also not be involved in the 
recruitment process or the conduct of the study. The 
results will be disseminated to patients via an open 
access publication and our local trials teams.
Outcome measures
Primary outcome measures
The primary outcome is the effectiveness in reducing 
postmenstrual spotting during the menstrual cycle 6 
months after randomisation. Postmenstrual spotting is 
defined as 2 or more days of intermenstrual spotting 
or as 2 or more days of brownish discharge immedi-
ately after the menstrual period or irregular light flow 
bleeding in case the total period of the menstrual 
bleeding exceeds 9 days. If the bleeding period is 
shorter than 10 days, the brownish discharge is not 
calculated as spotting. Effective case is defined as 
patients with a reduction of spotting by 50% or more. 
Effective rate is defined as the number of effective cases 
in the total number of follow- up cases. In the LNG- IUS 
52 mg group, if there is a regular menstrual cycle, the 
definition as reported above is used. If the bleeding 
pattern is irregular, the total unpredictable bleeding 
or spotting days per months (outside normal period) 
will be taken.
Secondary outcome measures
1. Menstrual pattern (menstrual cycle, duration of the 
menstruation), postmenstrual spotting, intermenstru-
al spotting, irregular light flow bleeding, total bleeding 
days per month,6 rate of amenorrhoea(amenorrhoea 
was defined as complete absence of bleeding or spot-
ting for at least 3 months).25
2. Total spotting days during one menstrual cycle 12 
months after randomisation.
3. Visual Analogue Scale (VAS) for discomfort from spot-
ting and chronic pelvic pain, urological symptoms.26
4. Women’s satisfaction with treatment (five- point Likert 
scale, very unsatisfied, unsatisfied, neutral, satisfied, 
very satisfied).27
5. Hormonal- related side effects such as mood changes, 
weight gain, breast pain and libido.28
6. Direct economic costs (including the costs of preop-
erative examination, medical consumption and the 
surgery).
7. Complications (including urinary tract injury, fever, in-
fection) and applied cointerventions.
Menstrual characteristics were self- recorded in a 
menstruation diary at 3, 6, 9 and 12 months after inclu-
sion and uploaded in an electronic data system.
Statistical consideration
Sample size calculation
Based on our previous prospective cohort study 
executed in 30:30 patients, the effective rate at 6 months 
after treatment of LNG- IUS 52 mg was 87.5%, while that 
of hysteroscopic niche resection was 73.3%. To show the 
superiority of LNG- IUS 52 mg group as compared with 
hysteroscopic niche resection group, with 1:1 allocation 
ratio, 80% statistical power and a two- sided significance 
level of 5%, a total of 188 patients (94 in each group) 
will need to be enrolled . Thus, 208 women (104 in each 
group) will need to be randomised,including 10% lost 
to follow- up or protocol variation.
Statistical methods
Analyses will be performed according to the intention- 
to- treat principle and additionally by per- protocol anal-
ysis. For continues variable, if normally distributed with 
equal variances we will use Student’s t- tests; otherwise 
Mann- Whitney U tests will be used. For categorical 
variables, we will use χ2 tests or Fisher’s exact test as 
appropriate. For categorical outcome, we will conduct 
a logistic regression analysis, in which we compare the 
factors of the effective group versus the control group. 
All tests will be performed two sided and a p<0.05 will 
be considered as statistically significant.
Data collection and management
At baseline obstetric history, indication for the CS(s), 
gestational age at time of CS(s), gynaecological symp-
toms before and after the last CS, menstrual pattern, 
previous therapies including medication or previous 
uterine surgery will be registered. The patient will 
receive digital secured questionnaires at baseline, 3, 
6, 9 and 12 months after randomisation about their 
menstrual pattern. The questionnaires include a vali-
dated menstrual bleeding score chart,6 VAS for discom-
fort from spotting, the severity of chronic pelvic pain,26 
satisfaction with treatment (five- point Likert scale),27 
and side effects of LNG- IUS 52 mg. Medical consulta-
tion, medication use and received additional treatments 
will be reported in an online diary. Any received addi-
tional treatment will be recorded in the case report file.
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If applicable, surgical outcomes such as satisfaction 
of the gynaecologist, surgical steps, complications 
and postoperative recovery will be recorded in the 
case report file. All additional therapies or transfer to 
another therapy after the first intervention will be regis-
tered in both groups, such as oral contraceptives or 
second surgical treatment.
Follow- up will be performed in both groups 3, 6, 9 and 
12 months after randomisation, all patients will undergo 
transvaginal sonography to record all niche features at 
baseline and/or LNG- IUS 52 mg position (figure 2).
Interim analysis and safety monitoring
Because of the relatively small sample size and the 
expected duration of inclusion, an interim analysis is not 
planned.
Hysteroscopy and LNG- IUS 52 mg insertion are 
both common practised procedures in gynaecology. 
Although both procedures are routine, complications 
may occur after the operation. The complications can 
be divided into two categories: complications associ-
ated with procedures and complications associated 
with distension media. Complications associated with 
procedures include uterine and bladder perforation, 
cervical laceration, pelvic infection and haemorrhage.29 
Complications associated with distension media can 
be prevented by monitoring the usage and fluid loss 
during the surgery.30
All serious adverse events will be reported to the 
Medical Ethics Committee. The Medical Ethics 
Committee can terminate the trial duly for safety 
reasons. Every observed or reported adverse event 
that link to suspected causal relationship with surgery 
or treatment will be registered. All adverse events will 
be followed until they have abated, or until a stable 
Figure 2 Flow chart. *Questionnaires: menstrual pattern, validated menstrual bleeding score chart,6 VAS score for discomfort 
from spotting, chronic pelvic pain,26 discomfort due to spotting and satisfaction with treatment (five- point Likert scale),27 side 
effects or complications after therapy. LNG- IUS, levonorgestrel intrauterine system; VAS, Visual Analogue Scale.
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situation has been reached. Depending on the event, 




The MIHYS NICHE trial is the first randomised controlled 
trial that will provide evidence for the effectiveness of 
LNG- IUS 52 mg versus hysteroscopic niche resection in 
reducing niche- related spotting symptoms.The trial is 
adequately powered based on a representative cohort 
study. Randomisation is performed with a use of alloca-
tion concealment with the help of web- based REDCap 
system, which will reduce the chance for bias.
We design MIHYS NICHE trial as an open- label trial 
both for patients and for researchers, but we used a blind 
method to evaluate the effect of treatment. This can 
reduce the bias of evaluation and ensure the authenticity 
of evaluation effect.
The MRI of CSD has not been commonly reported 
because of the price and little demand for investigations 
of AUB or other noncancerous pathologies.31 However, 
MRI has the advantages of high sensitivity, high resolu-
tion between different soft tissues and arbitrary section 
imaging, while the 3D MRI with the section of only 1 mm 
and 3D reconstruction are more accurate for the evalu-
ation of lesions with fine anatomical structure, minor 
lesions such as branches which can be missed by tradi-
tional MRI.
In most previous studies, hysteroscopic niche treatment 
is performed in patients with residual myometrium of at 
least 2.5–3 mm to avoid uterine perforation and bladder 
injury.6 28–35 However, some studies used 2 mm as the cut- 
off standard of residual myometrium in the hysteroscopic 
treatment.22 35 Based on our previous large cohort study, 
a minimal TRM of 2.2 mm resulted in significantly better 
outcomes after hysteroscopic niche resection.36 For this 
reason, we excluded women with a TRM of <2.2 mm. 
A strength of the study is that the learning curve was 
completed before starting this study. Two experienced 
gynaecologists performed more than 400 hysteroscopic 
niche resections together, so far related complications 
have not been reported.
Potential impact and implications
Although niche- related symptoms have been acknowl-
edged and various treatments have been implemented 
in recent years, there is still a lack of studies of evalu-
ating the effect of those treatments. LNG- IUS 52 mg has 
advantages that it does not require (general) anaesthesia 
or hospitalisation and that it is easy to insert. LNG- IUS 
52 mg also has the superiority of low risks of complica-
tions and low costs. However, it has not been supported 
by prospective studies so far whether LNG- IUS 52 mg is 
superior over a hysteroscopic niche resection.11 12 14–17 22 
Therefore, this randomised controlled study will provide 
the highest level of evidence- based medicine evidence for 
the treatment niche- related symptoms.
Ethics and dissemination
The study was approved by the local medical ethics 
committee and by the Institutional Review Board of the 
International Peace Maternity and Child Health Hospital, 
Shanghai, China (No. GKLW 2019-08). Participants will 
sign a written informed consent before participation. 
The results of this study will provide evidence for LNG- 
IUS 52 mg in treating women with niche- related postmen-
strual spotting.The results of this study will be submitted 
to a peer- reviewed journal for publication.
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